Editas Medicine, INC 8-K filings

Editas Medicine, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including director elections, advisory vote on executive compensation, and ratification of its independent auditor.

Editas Medicine announced the pricing of an underwritten public offering of common stock and accompanying warrants, aiming to raise approximately $125 million.

Editas Medicine has suspended and terminated its at-the-market offering program with TD Cowen, ceasing further sales of common stock under the existing agreement.

Editas Medicine announced robust preclinical data for its EDIT-401 candidate, showing significant reductions in key cardiovascular risk factors in non-human primates.

Editas Medicine presented new preclinical data for its hyperlipidemia candidate, EDIT-401, showing significant LDL cholesterol reduction in non-human primates.

Editas Medicine announced first quarter 2026 financial results, highlighting progress in its EDIT-401 gene editing program for hyperlipidemia and providing updates on intellectual property and upcoming data presentations.

Editas Medicine, Inc. announced the dismissal of Ernst & Young LLP as its independent registered public accounting firm and the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026.

Editas Medicine announced the U.S. Patent and Trademark Office reaffirmed the Broad Institute's inventorship priority for CRISPR/Cas9 gene editing in human cells, reinforcing Editas's intellectual property.

Editas Medicine reported third-quarter 2025 financial results and significant progress on its lead gene-editing candidate, EDIT-401, for LDL cholesterol reduction, extending its cash runway into Q3 2027.

Editas Medicine announced robust preclinical proof-of-concept data for its gene-editing therapy EDIT-401, showing significant LDL-cholesterol reduction.

Editas Medicine announced the nomination of EDIT-401, an LDLR-targeted gene editing medicine, as its lead in vivo development candidate, showing significant LDL-C reduction in preclinical studies.

Editas Medicine reports Q2 2025 financial results, advancing gene editing programs with a lead candidate selection in September and a strong cash runway into Q2 2027.

Editas Medicine announced new preclinical data demonstrating therapeutically relevant levels of gene editing in non-human primates for sickle cell disease and beta thalassemia, exceeding predicted therapeutic thresholds.

Editas Medicine, Inc. announced that its stockholders approved a significant increase in authorized common stock and an amended stock incentive plan, alongside the election of directors and executive compensation matters, at its Annual Meeting on May 29, 2025.

Editas Medicine reports new in vivo data demonstrating therapeutically relevant levels of HBG1/2 promoter editing in hematopoietic stem cells using a targeted lipid nanoparticle delivery system.

Editas Medicine reports successful in vivo CRISPR editing resulting in functional upregulation of a liver target protein and meaningful reduction of a disease-associated biomarker in mice.

Editas Medicine reports its first quarter 2025 financial results, highlights preclinical data on in vivo gene editing, and anticipates declaring two in vivo gene editing development candidates in mid-2025.

Editas Medicine announces the resignation of CFO Erick Lucera and the appointment of Amy Parison as the new CFO and Treasurer, effective March 28, 2025.

Editas Medicine reports Q4 and full year 2024 results, highlighting a strategic focus on in vivo gene editing and a strong cash position extending into Q2 2027.

Editas Medicine has released new in vivo preclinical proof of concept data, along with anticipated 2025 milestones and three-year strategic priorities.

Editas Medicine's Chief Medical Officer, Baisong Mei, will step down effective December 31, 2024, with a transition period extending to January 31, 2025, and a separation agreement outlining his benefits.

Editas Medicine is discontinuing its ex vivo reni-cel program, reducing its workforce by approximately 65%, and shifting its focus to in vivo gene editing to extend its cash runway into the second quarter of 2027.

Editas Medicine updated its bylaws to clarify definitions and reported positive clinical data from its RUBY trial for a sickle cell disease treatment.

Editas Medicine announced its third quarter 2024 financial results and provided updates on its clinical and preclinical programs, including achieving in vivo preclinical proof of concept for its gene editing technology.

Editas Medicine announced the achievement of in vivo preclinical proof of concept for its gene editing technology and initiated a process to partner or out-license its reni-cel program.

Editas Medicine has entered into an agreement with DRI Healthcare Trust to monetize future license fees from Vertex Pharmaceuticals, securing $57 million in upfront capital.

Editas Medicine announced its second quarter 2024 financial results and provided updates on its clinical programs, including the RUBY and EdiTHAL trials, and its in vivo preclinical program.

Akshay Vaishnaw has resigned from the Editas Medicine Board of Directors, effective June 30, 2024.

Editas Medicine reported promising safety and efficacy data from its RUBY and EdiTHAL trials for Reni-cel, a gene-editing therapy for sickle cell disease and beta thalassemia, at the European Hematology Association Annual Congress.

Editas Medicine held its annual meeting on May 30, 2024, electing three Class II directors, approving executive compensation on an advisory basis, and ratifying Ernst & Young as its auditor.